听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览DRUGS期刊下所有文献
  • Lumasiran: First Approval.

    abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01463-0

    authors: Scott LJ,Keam SJ

    更新日期:2021-01-06 00:00:00

  • Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.

    abstract::Gene rearrangements involving the neurotrophic receptor kinase genes NTRK1, NTRK2, and NTRK3 (referred to as TRK, encoding TRKA, TRKB, and TRKC, respectively) result in highly oncogenic fusions. TRK fusions are rare, with a prevalence of < 1% in solid tumors. Detection of TRK fusions can be based on fluorescence in-si...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01459-w

    authors: Rohrberg KS,Lassen U

    更新日期:2021-01-05 00:00:00

  • Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.

    abstract::Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse ra...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01437-2

    authors: Syed YY

    更新日期:2021-01-01 00:00:00

  • Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.

    abstract::Immunotherapies have shown remarkable success in the treatment of multiple cancer types; however, despite encouraging preclinical activity, registration trials of immunotherapy in prostate cancer have largely been unsuccessful. Sipuleucel-T remains the only approved immunotherapy for the treatment of asymptomatic or m...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01456-z

    authors: Rathi N,McFarland TR,Nussenzveig R,Agarwal N,Swami U

    更新日期:2020-12-28 00:00:00

  • Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon.

    abstract:INTRODUCTION:Several pharmacological treatments aiming at a better symptomatic control of osteoarthritis (OA) are used in daily practice but their efficacy is often disputed. The purpose of this network meta-analysis (NMA) is to assess the efficacy on pain and function of the drugs that are most widely prescribed again...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01423-8

    authors: Beaudart C,Lengelé L,Leclercq V,Geerinck A,Sanchez-Rodriguez D,Bruyère O,Reginster JY

    更新日期:2020-12-01 00:00:00

  • Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.

    abstract::Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01443-4

    authors: Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JA

    更新日期:2020-11-28 00:00:00

  • Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

    abstract::Chronic spontaneous urticaria (CSU) is characterized by the presence of wheals, angioedema, or both for at least 6 weeks. It may persist for a long time-up to 50% of the patients have been reported to be symptomatic 5 years after the onset. Some patients can suffer more than one episode of CSU during their lifetime. C...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01387-9

    authors: Giménez-Arnau AM,Salman A

    更新日期:2020-11-01 00:00:00

  • Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.

    abstract::Approximately 70% of invasive breast cancers have some degree of dependence on the estrogen hormone for cell proliferation and growth. These tumors have estrogen and/or progesterone receptors (ER/PR+), generally referred to as hormone receptor positive (HR+) tumors, as indicated by the presence of positive staining an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01394-w

    authors: Nunnery SE,Mayer IA

    更新日期:2020-11-01 00:00:00

  • Clascoterone: First Approval.

    abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01417-6

    authors: Dhillon S

    更新日期:2020-11-01 00:00:00

  • Management of Thrombotic Complications in COVID-19: An Update.

    abstract::Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01377-x

    authors: Hajra A,Mathai SV,Ball S,Bandyopadhyay D,Veyseh M,Chakraborty S,Lavie CJ,Aronow WS

    更新日期:2020-10-01 00:00:00

  • Correction to: Deprescribing Opioids in Chronic Non‑cancer Pain: Systematic Review of Randomised Trials.

    abstract::Page 9, Fig. 2, which originally appeared as. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01416-7

    authors: Mathieson S,Maher CG,Ferreira GE,Hamilton M,Jansen J,McLachlan AJ,Underwood M,Lin CC

    更新日期:2020-10-01 00:00:00

  • Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::The original article can be found online. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01407-8

    authors: Scott LJ

    更新日期:2020-09-01 00:00:00

  • Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates.

    abstract::Chronic pancreatitis is a clinical entity that results from the progressive inflammation and irreversible fibrosis of the pancreas resulting from the cumulative injury sustained by the pancreas over time. It is an illness with variable presentations that can severely impact quality of life, while its long-term complic...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01360-6

    authors: Kichler A,Jang S

    更新日期:2020-08-01 00:00:00

  • Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?

    abstract::Janus kinase (JAK) is a signal transducer and activator of a protein transcription system that transduces signals from cell surface cytokine and growth factor receptors to the nucleus. Recently developed JAK inhibitors (JAKinibs) inhibit JAKs non-selectively or selectively and down-regulate the effects of correspondin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01349-1

    authors: Harigai M,Honda S

    更新日期:2020-08-01 00:00:00

  • Spread the Word: There Are Two Opioid Crises!

    abstract::Pain is associated with emotional and physical suffering that severely impacts quality of life. Many guidelines for the treatment of moderate to severe cancer pain indicate the use of opioids. For a small proportion of the global population, opioids are readily accessible, but are consequently also subject to risk of ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01342-8

    authors: Marchetti Calônego MA,Sikandar S,Ferris FD,Moreira de Barros GA

    更新日期:2020-08-01 00:00:00

  • Sacituzumab Govitecan: First Approval.

    abstract::Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the US...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01337-5

    authors: Syed YY

    更新日期:2020-07-01 00:00:00

  • Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.

    abstract::Patients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01320-0

    authors: Somasundaram A,Socinski MA,Villaruz LC

    更新日期:2020-06-01 00:00:00

  • Correction to: Isatuximab: First Approval.

    abstract::In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01325-9

    authors: Dhillon S

    更新日期:2020-06-01 00:00:00

  • New and Emerging Therapies for Alopecia Areata.

    abstract::Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01293-0

    authors: Pourang A,Mesinkovska NA

    更新日期:2020-05-01 00:00:00

  • Cenegermin: A Review in Neurotrophic Keratitis.

    abstract::Cenegermin (Oxervate™), an ophthalmic solution containing 20 µg/mL of recombinant human nerve growth factor (rhNGF), is the first drug to be approved for the treatment of neurotrophic keratitis (NK; also referred to as neurotrophic keratopathy). In the registration trials, the majority of adults with moderate or sever...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01289-w

    authors: Deeks ED,Lamb YN

    更新日期:2020-04-01 00:00:00

  • Lemborexant: First Approval.

    abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01276-1

    authors: Scott LJ

    更新日期:2020-03-01 00:00:00

  • Correction to: Pexidartinib: First Approval.

    abstract::The original article has been corrected. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01280-5

    authors: Lamb YN

    更新日期:2020-03-01 00:00:00

  • Avapritinib: First Approval.

    abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01275-2

    authors: Dhillon S

    更新日期:2020-03-01 00:00:00

  • Dulaglutide: A Review in Type 2 Diabetes.

    abstract::Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monot...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01260-9

    authors: Scott LJ

    更新日期:2020-02-01 00:00:00

  • Cenobamate: First Approval.

    abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01250-6

    authors: Keam SJ

    更新日期:2020-01-01 00:00:00

  • Sotagliflozin: A Review in Type 1 Diabetes.

    abstract::Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01230-w

    authors: Deeks ED

    更新日期:2019-12-01 00:00:00

  • Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?

    abstract::Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination. Recently, it could be shown that immunotherapy works as consolidation after chemoradiotherapy in locally adv...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01222-w

    authors: Heigener DF,Reck M

    更新日期:2019-12-01 00:00:00

  • Immunotherapy Against Gliomas: is the Breakthrough Near?

    abstract::Immunotherapeutic approaches have been, and continue to be, aggressively investigated in the treatment of infiltrating gliomas. While the results of late-phase clinical studies have been disappointing in this disease space thus far, the success of immunotherapies in other malignancies as well as the incremental gains ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01203-z

    authors: Lukas RV,Wainwright DA,Horbinski CM,Iwamoto FM,Sonabend AM

    更新日期:2019-11-01 00:00:00

  • Tenapanor: First Approval.

    abstract::The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA®] and for hyperphosphataemia in patients with chronic kidney disease (CKD) on dialysis or with end stage re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01215-9

    authors: Markham A

    更新日期:2019-11-01 00:00:00

  • Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer.

    abstract::The article Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer, written by Connie Kang, Sohita Dhillon and Emma D. Deeks, was originally published Online First without open access. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-019-01199-6

    authors: Kang C,Dhillon S,Deeks ED

    更新日期:2019-10-01 00:00:00

  • Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.

    abstract::An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01201-1

    authors: Hoy SM

    更新日期:2019-10-01 00:00:00

  • Emicizumab: A Review in Haemophilia A.

    abstract::Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01200-2

    authors: Blair HA

    更新日期:2019-10-01 00:00:00

  • Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).

    abstract::Interstitial lung disease (ILD) can be associated with all connective tissue diseases and is an important cause of morbidity and mortality. The management of connective tissue disease-interstitial lung disease (CTD-ILD) is challenging due substantial heterogeneity in disease behaviour and paucity of controlled clinica...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01178-x

    authors: Jee AS,Corte TJ

    更新日期:2019-09-01 00:00:00

  • Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.

    abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01164-3

    authors: Morris TA,Khoo C,Solomon BJ

    更新日期:2019-08-01 00:00:00

  • Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

    abstract::Glucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatme...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01145-6

    authors: Raterman HG,Bultink IEM,Lems WF

    更新日期:2019-07-01 00:00:00

  • Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.

    abstract::Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01130-z

    authors: Schehlein EM,Robin AL

    更新日期:2019-07-01 00:00:00

  • Damoctocog Alfa Pegol: A Review in Haemophilia A.

    abstract::Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01152-7

    authors: Paik J,Deeks ED

    更新日期:2019-07-01 00:00:00

  • Peficitinib: First Global Approval.

    abstract::Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01131-y

    authors: Markham A,Keam SJ

    更新日期:2019-06-01 00:00:00

  • Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

    abstract::Increases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Che...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01132-x

    authors: Blanton HL,Brelsfoard J,DeTurk N,Pruitt K,Narasimhan M,Morgan DJ,Guindon J

    更新日期:2019-06-01 00:00:00

  • Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.

    abstract::Pegaspargase (Oncaspar®), a pegylated form of native Escherichia coli-derived L-asparaginase (hereafter referred as E. coliL-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative to E....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01120-1

    authors: Heo YA,Syed YY,Keam SJ

    更新日期:2019-05-01 00:00:00

634 条记录 1/16 页 « 12345678...1516 »